ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO1135

Association of Renal Function with Mortality Among Hospitalized Patients Treated with Remdesivir for COVID-19

Session Information

  • COVID-19 - II
    November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Gonzalez Suarez, Maria Lourdes, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Mara, Kristin C., Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Rivera, Christina, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Chesdachai, Supavit, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Draper, Evan, Mayo Clinic Minnesota, Rochester, Minnesota, United States
  • Razonable, Raymund, Mayo Clinic Minnesota, Rochester, Minnesota, United States

Renal dysfunction is associated with poor outcomes in patients with coronavirus disease 2019 (COVID-19). In an effort to improve outcomes, intravenous remdesivir has been broadly used off label for the treatment of COVID-19 in patients with low estimated glomerular filtration rate (eGFR). Our study assessed the outcomes of patients with low eGFR after treatment with remdesivir for COVID-19.


We conducted an observational, retrospective, cohort study of adults hospitalized with COVID-19 treated with at least one dose of remdesivir between 11/6/2020, and 11/5/2021. Electronic medical records were reviewed to obtain patient characteristics, laboratory data, and outcomes. Primary endpoint was all-cause mortality by day 28. Multivariable logistic regression was used to evaluate association among groups.


We studied 3024 patients hospitalized with COVID-19 and treated with remdesivir. Median age was 67 [IQR 55, 77] years; 42.7% were women, 88.6% were white. Median eGFR was 76.6 mL/min/1.73 m2 [IQR 52.5, 95.2]; 67.2% of patients had eGFR ≥ 60, while 9% had eGFR <30. All-cause mortality by day 28 was 8.7%. All-cause mortality rates were significantly higher among patients with impaired renal function (Odds Ratio [OR] 1.94 for patients with eGFR 30-59; OR 1.94 for eGFR 15-29; OR 3.62 for eGFR <15 and OR 9.08 for patients on dialysis) compared to patients with eGFR ≥60 (all p<0.01) (Figure 1).


Lower eGFR is an independent risk factor for mortality in COVID-19 despite treatment with remdesivir. These observations suggest that, even with the availability of effective antiviral treatment, prevention of COVID-19 remains a major goal especially among those with impaired renal function.

Overall survival according to eGFR


  • Commercial Support – Gilead